Examining anticoagulation in pregnant women using Lovenox three times a day
Official title: Anticoagulation Profile in Pregnant Women Treated With Three Times a Day of Low Molecular Weight Heparin (LMWH)
Run by University of California, Irvine · NCT04861103 · Data updated 2026-11-12
This study tests if giving pregnant women Lovenox three times a day helps keep their blood thinner and safer from clots compared to the usual twice-daily dose.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 12 (estimated) |
| Sponsor | University of California, Irvine Academic / other |
| Locations | 1 site (Orange, California) |
| Status | Recruiting |
| Started | October 1, 2020 |
| Main results expected | December 31, 2026 |
| Study ends | July 31, 2027 |
| Registry record updated | October 29, 2025 |
| Trial ID | NCT04861103 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are nulliparous or multiparous women aged 18 or older with a single intrauterine pregnancy requiring therapeutic low molecular weight heparin.
✕Probably not a fit
Patients who are pregnant with multiples, under 18 years old, have a history of Heparin Induced Thrombocytopenia, or are allergic to enoxaparin may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the anticoagulation profile of pregnant women who are treated with low molecular weight heparin (Lovenox) administered three times a day. Given the increased risk of blood clots during pregnancy, the study aims to determine if more frequent dosing can achieve adequate medication levels throughout the day. The research focuses on women who require therapeutic doses of Lovenox and evaluates the effectiveness of this dosing strategy compared to traditional twice-daily dosing. The study is conducted at the University of California, Irvine.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the risk of blood clots in pregnant women by ensuring more consistent anticoagulation levels.
How similar studies have gone: While there is limited data on this specific dosing strategy, previous studies indicate that many patients do not achieve adequate anticoagulation levels with current dosing recommendations, suggesting a need for further investigation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Nulliparous or multiparous women with single intrauterine pregnancies who require therapeutic low molecular weight heparin during their pregnancy. * Participants must be age 18 or older. Exclusion Criteria: * Women with multiples. * Women less than age 18 * History of Heparin Induced Thrombocytopenia (HIT) * Allergy to enoxaparin
Where it's running
-
University of California Irvine
Orange, California, United States Recruiting
Study contacts
- Principal investigator: Afshan Hameed — University of California, Irvine
- Study coordinator: Lizette Spears
- Email: lspiers@hs.uci.edu
- Phone: 714.456.5694
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
NOURISH: a community partnership to improve nutrition and glycemic control in pregnant women with pregestational diabetes
Aiming to test a healthcare-community program that delivers healthy food weekly and provides nutrition education to pregnant women with type 1 or type 2 diabetes who have food insecurity, to improve blood sugar and pregnancy outcomes.
-
MOCHA: Inpatient Mental Health Care for High-Risk Pregnancy
This study tests a collaborative mental health program for pregnant or recently postpartum patients hospitalized for medical problems to see if it can be delivered feasibly and acceptably.
-
Catheter ablation plus LAAC vs anticoagulation in frail elderly A-fib patients
This study tests whether adding left atrial appendage closure to ablation is as good as using long-term blood thinners in frail people aged 75 and up with atrial fibrillation.
-
Permissive versus strict blood sugar control during labor for pregnant people with type 1 diabetes
This trial will test whether allowing slightly higher blood sugars (70–140 mg/dL) during labor is as safe for newborns as keeping tighter control (70–110 mg/dL) for pregnant people with type 1 diabetes using hybrid closed‑loop insulin systems.
-
Impact of Automated Insulin Delivery on Pregnancy Outcomes
This study looks at how using automated insulin delivery systems during pregnancy affects the health of both mothers with type 1 diabetes and their babies.
-
Comparing Metformin and Insulin for Gestational Diabetes Treatment
This study is testing whether metformin is as effective as insulin for treating gestational diabetes in pregnant people and looks at how safe both treatments are for mothers and their babies.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.